Related Experiment Video
Updated: Feb 12, 2026

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
Published on: February 23, 2024
To chelate or not to chelate in MDS: That is the question!
Amer M Zeidan1, Elizabeth A Griffiths2
1Section of Hematology, Department of Medicine, Yale University, Yale Cancer Center, New Haven, CT, USA.
Abstract:
Myelodysplastic syndromes (MDS) are a heterogeneous group of hemopathies that exhibit physical manifestations with clinical consequences of bone marrow failure and inherent risk of progression to acute myeloid leukemia. Iron overload (IO) is common in MDS due to chronic transfusion support and disease-related alterations in iron metabolism. IO has been conclusively associated with inferior outcomes among MDS patients. Despite lack of randomized trials showing a survival impact of iron chelation therapy (ICT), ICT is recommended by experts and guidelines for select MDS patients with IO and is often used. The availability of effective oral ICT agents has reignited the controversy regarding ICT use in patients with MDS and IO. Here we summarize the studies evaluating the value of ICT in MDS and suggest a practical approach for use of these therapies. We also highlight controversies regarding use of ICT in MDS and discuss some ongoing efforts to answer these questions.
More Related Videos
Related Concept Videos
Complexation Equilibria: The Chelate Effect
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
The Scientific Method
The Scientific Method
Generally, predictions are tested using carefully-designed experiments. Based on the outcome of these...
Archival Research
Surveys

